Modalis Therapeutics (TSE:4883) ROCE % : -112.91% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Modalis Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -112.91%.

Modalis Therapeutics ROCE % Historical Data

The historical data trend for Modalis Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Modalis Therapeutics ROCE % Chart

Modalis Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.23

-8.73

-12.30

-60.89

-99.10

Modalis Therapeutics Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial														-74.70	-75.74	-95.24	-168.18	-112.91

Modalis Therapeutics ROCE % Calculation

Modalis Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-2386.193	/	( ( (3129.833 - 141.84)	+	(2025.925 - 198.101) )	/ 2 )
	=	-2386.193	/	( (2987.993	+	1827.824)	/ 2 )
	=	-2386.193	/	2407.9085
	=	-99.10 %

Modalis Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-1826.404	/	( ( (2025.925 - 198.101)	+	(1559.124 - 151.687) )	/ 2 )
	=	-1826.404	/	( ( 1827.824	+	1407.437 )	/ 2 )
	=	-1826.404	/	1617.6305
	=	-112.91 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Modalis Therapeutics (TSE:4883) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Modalis Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Modalis Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Modalis Therapeutics (TSE:4883) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026

Website

https://www.modalistx.com

Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.

Modalis Therapeutics (TSE:4883) Headlines

No Headlines